<div id="readability-page-1"><p>Serina Therapeutics (SER) stock rocketed on Thursday after the pharmaceutical company announced clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for SER-252. This is an investigational therapy for advanced Parkinson's disease.</p><h3>Claim 50% Off TipRanks Premium</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>Serina Therapeutics noted that this approval allows the company to move forward with a Phase 1b registrational clinical study evaluating SER-252 in patients with advanced Parkinson's disease. This follows several communications with the FDA for the trial in an effort to reach a New Drug Application (NDA) for SER-252.</p> <p>Steve Ledger, CEO of Serina Therapeutics, said, &#34;FDA clearance of the IND is a major milestone for Serina and underscores the promise of the SER-252 program. As we initiate our registrational study, we will begin generating meaningful clinical data for SER-252 in patients with advanced Parkinson's disease. With FDA alignment on a registrational development strategy under a 505(b)(2) NDA pathway, we believe SER-252 has a clear and efficient path forward toward addressing a significant unmet medical need.&#34;</p> <h2><strong>Serina Therapeutics Stock Movement Today</strong></h2> <p>Serina Therapeutics stock was up 37.87% on Thursday, extending a 96.03% rally year-to-date. However, the shares were still down 40.87% over the past 12 months.</p> <p>With today's news came heavy trading of SER stock, as more than 45 million shares changed hands, compared to a three-month daily average trading volume of about 24,000 units.</p></div>

ARKG

SBIO

<p>Serina Therapeutics (SER) stock surged 37.87% on Thursday after receiving FDA clearance for its IND application for SER-252, a therapy for advanced Parkinson's disease. This approval allows the company to proceed with a Phase 1b clinical study. CEO Steve Ledger highlighted the significance of this milestone and the potential of SER-252 to meet an unmet medical need. Despite the recent rally, the stock is down 40.87% over the past year, with over 45 million shares traded, far exceeding the average volume of 24,000.</p>

This Is Why Serina Therapeutics Stock (SER) Rocketed Today